Chongqing Lummy Pharmaceutical (300006) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) has a cash flow conversion efficiency ratio of -0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-14.90 Million ≈ $-2.18 Million USD) by net assets (CN¥1.85 Billion ≈ $271.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 300006 company net worth for the company's overall valuation and market capitalisation.
Chongqing Lummy Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Chongqing Lummy Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Chongqing Lummy Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chongqing Lummy Pharmaceutical ranked by their cash flow conversion efficiency. Explore Chongqing Lummy Pharmaceutical cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Advance Gearbox Group Co Ltd
SHG:601177
|
0.028x |
|
Shanghai Xinhua Media Co Ltd
SHG:600825
|
-0.002x |
|
Fujian Apex Software Co Ltd
SHG:603383
|
-0.023x |
|
Chengdu B-ray Media Co Ltd
SHG:600880
|
-0.001x |
|
Qiaoyin Environmental Tech Co Ltd
SHE:002973
|
0.015x |
|
Power Mech Projects Limited
NSE:POWERMECH
|
0.087x |
|
Si-Bone Inc
NASDAQ:SIBN
|
0.004x |
|
BMC Medical Co. Ltd. A
SHE:301367
|
N/A |
Annual Cash Flow Conversion Efficiency for Chongqing Lummy Pharmaceutical (2006–2024)
The table below shows the annual cash flow conversion efficiency of Chongqing Lummy Pharmaceutical from 2006 to 2024. View Chongqing Lummy Pharmaceutical (300006) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.88 Billion ≈ $275.59 Million |
CN¥185.03 Million ≈ $27.08 Million |
0.098x | +155.72% |
| 2023-12-31 | CN¥2.12 Billion ≈ $310.54 Million |
CN¥81.53 Million ≈ $11.93 Million |
0.038x | +46.92% |
| 2022-12-31 | CN¥2.18 Billion ≈ $319.73 Million |
CN¥57.13 Million ≈ $8.36 Million |
0.026x | -46.58% |
| 2021-12-31 | CN¥2.21 Billion ≈ $323.70 Million |
CN¥108.28 Million ≈ $15.84 Million |
0.049x | -73.15% |
| 2020-12-31 | CN¥1.23 Billion ≈ $180.22 Million |
CN¥224.54 Million ≈ $32.86 Million |
0.182x | +30.35% |
| 2019-12-31 | CN¥1.65 Billion ≈ $241.99 Million |
CN¥231.30 Million ≈ $33.85 Million |
0.140x | +6.75% |
| 2018-12-31 | CN¥1.72 Billion ≈ $252.28 Million |
CN¥225.89 Million ≈ $33.05 Million |
0.131x | +267.72% |
| 2017-12-31 | CN¥1.72 Billion ≈ $252.11 Million |
CN¥61.39 Million ≈ $8.98 Million |
0.036x | -52.53% |
| 2016-12-31 | CN¥1.67 Billion ≈ $245.00 Million |
CN¥125.66 Million ≈ $18.39 Million |
0.075x | +599.18% |
| 2015-12-31 | CN¥1.69 Billion ≈ $247.28 Million |
CN¥-25.41 Million ≈ $-3.72 Million |
-0.015x | +69.04% |
| 2014-12-31 | CN¥1.02 Billion ≈ $148.81 Million |
CN¥-49.38 Million ≈ $-7.23 Million |
-0.049x | -173.18% |
| 2013-12-31 | CN¥1.13 Billion ≈ $164.73 Million |
CN¥74.70 Million ≈ $10.93 Million |
0.066x | +159.29% |
| 2012-12-31 | CN¥710.51 Million ≈ $103.97 Million |
CN¥18.18 Million ≈ $2.66 Million |
0.026x | +42.56% |
| 2011-12-31 | CN¥660.17 Million ≈ $96.60 Million |
CN¥11.85 Million ≈ $1.73 Million |
0.018x | -73.23% |
| 2010-12-31 | CN¥561.59 Million ≈ $82.18 Million |
CN¥37.66 Million ≈ $5.51 Million |
0.067x | -5.73% |
| 2009-12-31 | CN¥525.08 Million ≈ $76.84 Million |
CN¥37.35 Million ≈ $5.47 Million |
0.071x | -43.18% |
| 2008-12-31 | CN¥137.79 Million ≈ $20.16 Million |
CN¥17.25 Million ≈ $2.52 Million |
0.125x | -37.70% |
| 2007-12-31 | CN¥107.91 Million ≈ $15.79 Million |
CN¥21.68 Million ≈ $3.17 Million |
0.201x | +66.59% |
| 2006-12-31 | CN¥64.39 Million ≈ $9.42 Million |
CN¥7.77 Million ≈ $1.14 Million |
0.121x | -- |
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more